Inside the research

West Pharmaceutical Services, Inc.

WST Research profile · latest available data

Price overview

$370.44

▼ -3.16 (-0.8%)

52w hi$375.87
52w lo$230.63
Vol434.00K
As of25 Sep 2026

The Verdict

Hold

Our score +0.34

Short+0.27
Medium+0.45
Long+0.28

computed 2026-09-27

Key fundamentals

West Pharmaceutical Services, Inc.

Healthcare · Medical Instruments & Supplies

Market cap$26.07B
Enterprise value$25.95B
Trailing P/E47.43x
Forward P/E37.11x
EV / EBITDA28.45x
P / S (ttm)7.84x
Profit margin17.0%
Return on equity19.1%
Revenue growth+13.8%
Earnings growth+18.1%
Debt / equity10.59

Layer Breakdown

LayerRawContribution
Fundamental+0.21
Sector+0.08
Technical+0.22
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

United States · www.westpharma.com

Risk Metrics

Beta vs SPX0.60
Corr SPX0.21
Annual vol47.0%
Annual ret+21.3%
Sharpe0.45
Max DD-45.3%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$349.85
High / Low$400.00 / $310.00
Median$350.00
Analysts13
Strong Buy2
Buy10
Hold3
Sell0
Strong Sell0

Recent rating actions

2026-04-27Barclays→ Equal-Weight
2026-04-14Barclays→ Equal-Weight
2026-02-13Barclays→ Equal-Weight
2026-02-03Evercore ISI Group→ Outperform
2025-12-02Morgan Stanley→ Equal-Weight
2025-10-29TD Cowen→ Buy

Material Events

DateEvent8-K
2026-07-23Earnings Release, Reg FD Disclosure…read
2026-07-14Material Agreement, Exhibitsread
2026-06-01Officer / Director Change, Reg FD Disclosure…read
2026-05-111.05, Reg FD Disclosure…read
2026-05-05Shareholder Vote, Exhibitsread
2026-04-23Earnings Release, Reg FD Disclosure…read
2026-03-09Officer / Director Change, Reg FD Disclosure…read
2026-02-12Earnings Release, Reg FD Disclosure…read
2025-10-23Earnings Release, Reg FD Disclosure…read
2025-09-11Officer / Director Change, Exhibitsread
2025-07-24Earnings Release, Reg FD Disclosure…read
2025-07-21Officer / Director Change, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-11McMahon Robert W.SVP & Chief Financial OffOption exercise794—
2026-08-11McMahon Robert W.SVP & Chief Financial OffWithheld for tax346$121.40K
2026-08-11McMahon Robert W.SVP & Chief Financial OffOption exercise6.35K—
2026-08-11McMahon Robert W.SVP & Chief Financial OffWithheld for tax2.76K$971.07K
2026-05-12Campbell Shane AldenSVP, Proprietary SegmentOption exercise296—
2026-05-12Campbell Shane AldenSVP, Proprietary SegmentWithheld for tax84$26.32K
2026-05-12Campbell Shane AldenSVP, Proprietary SegmentOption exercise474—
2026-05-12Campbell Shane AldenSVP, Proprietary SegmentWithheld for tax135$42.11K
2026-05-04Pucci PaoloGrant791—
2026-05-04Michels Douglas AGrant791—

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders0
Top-5 share0.0%
HHI0 (—)

Dividends

Yield (TTM)0.18%
$ / share (TTM)$0.66
5y CAGR+5.5%

Annual dividend per share

2021$0.69
2022$0.73
2023$0.77
2024$0.81
2025$0.85
2026$0.44

SEC Filings

DateFormDoc
2026-08-124view
2026-07-238-Kview
2026-07-2310-Qview
2026-07-148-Kview
2026-07-014view
2026-06-018-Kview
2026-05-208-K/Aview
2026-05-144view
2026-05-118-Kview
2026-05-064view
2026-05-064view
2026-05-064view
2026-05-064view
2026-05-064view
2026-05-064view

The Long Run

FY 2010–2025 · 15 years

LineLatestCAGRTrend
Revenue$2.89B+7.5%
Gross profit$1.13B+9.9%
Operating income$584.90M+11.7%
Net income$493.70M+33.8%
Cash from ops$776.50M+13.1%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$372.01$372.14$368.45$370.44434.00K
Sep 24$378.67$382.71$370.71$373.60715.90K
Sep 23$370.93$376.06$368.20$375.87876.90K
Sep 22$367.42$375.40$365.26$371.09734.70K
Sep 21$363.78$366.12$361.05$361.78506.80K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →